STOCK TITAN
  1. Home
  2. News
  3. MASS

908 Devices Inc - MASS STOCK NEWS

Welcome to our dedicated news page for 908 Devices (Ticker: MASS), a resource for investors and traders seeking the latest updates and insights on 908 Devices.

Our selection of high-quality news articles is accompanied by an expert summary from Rhea-AI, detailing the impact and sentiment surrounding the news at the time of release, providing a deeper understanding of how each news could potentially affect 908 Devices's stock performance. The page also features a concise end-of-day stock performance summary, highlighting the actual market reaction to each news event. The list of tags makes it easy to classify and navigate through different types of news, whether you're interested in earnings reports, stock offerings, stock splits, clinical trials, fda approvals, dividends or buybacks.

Designed with both novice traders and seasoned investors in mind, our page aims to simplify the complex world of stock market news. By combining real-time updates, Rhea-AI's analytical insights, and historical stock performance data, we provide a holistic view of 908 Devices's position in the market.

News
908 Devices to Report First Quarter 2024 Financial Results on April 30, 2024
Rhea-AI Summary
908 Devices Inc. (Nasdaq: MASS) will report its first quarter 2024 financial results on April 30, 2024. The company specializes in handheld and desktop devices for chemical and biochemical analysis. The conference call will be webcasted at 8:30 a.m. Eastern Time / 5:30 a.m. Pacific Time, with live audio available on their website. The webcast will be archived for replay within 24 hours.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-0.54%
Tags
conferences earnings
-
News
908 Devices Trace Chemical Identification Technology Adopted by European Agencies
Rhea-AI Summary
908 Devices Inc. (Nasdaq: MASS) announces international adoption of MX908 for trace chemical detection and identification, with contracts from DrugDetect EU and NATO Support and Procurement Agency. MX908 deployed in military and correctional settings to detect drugs like cocaine, heroin, and methamphetamine. Operational validation shows effectiveness in identifying trace drug samples. NSPA contract streamlines procurement for NATO member states and allies. MX908 used for CBRNE applications in various environmental conditions. CEO Kevin J. Knopp highlights the versatility and life-saving capabilities of the technology.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
5.41%
Tags
none
-
News
908 Devices Reports Fourth Quarter and Full Year 2023 Financial Results and Provides 2024 Revenue Outlook
Rhea-AI Summary
908 Devices Inc. (MASS) reported a 23% revenue increase in Q4 2023 driven by 57% growth in handheld revenue. The company saw a 28% growth in handheld revenue for the full year 2023. Despite near-term challenges in life science industries, 908 Devices launched two desktop devices. The company ended 2023 with $145.7 million in cash and expanded its global presence. Collaboration with Cellares was announced for large-scale cell therapy manufacturing.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-3.73%
Tags
earnings
News
908 Devices and Cellares Collaborate to Integrate In-line Monitoring of Bioprocess Parameters into the Cell Shuttle, Cellares’ Fully Integrated Cell Therapy Manufacturing Platform
Rhea-AI Summary
908 Devices Inc. and Cellares announce a collaboration to integrate in-line monitoring of key cell culture parameters into Cellares' Cell Shuttle system. The partnership aims to enhance efficiency, safety, and cost-effectiveness in large-scale cell therapy manufacturing.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-1.74%
Tags
none
-
News
908 Devices to Participate in Upcoming Investor Conferences
Rhea-AI Summary
908 Devices Inc. (MASS) will participate in investor conferences including Cowen 44th Annual Healthcare Conference and KeyBanc Life Sciences & MedTech Forum. Interested parties can access live and archived webcasts on the company's website.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
2.16%
Tags
conferences
-
News
908 Devices to Report Fourth Quarter and Full Year 2023 Financial Results on March 5, 2024
Rhea-AI Summary
908 Devices Inc. (MASS) will announce Q4 and full-year 2023 financial results on March 5, 2024, with a webcast conference call. The live audio will be accessible on the company's website.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-1.52%
Tags
conferences earnings
News
908 Devices Announces MX908 Integration Capabilities
Rhea-AI Summary
908 Devices Inc. (Nasdaq: MASS) broadens the reach of trace detection and identification at the point of need through the addition of a weatherproof, digital communications port to its handheld MX908 device. This allows companies to integrate the device into their systems for enhanced safety. The recent collaboration with RADēCO, Inc. and DualDraw represents the first adoption for MX908 integrated systems, increasing accessibility to the company's proprietary mass spectrometry technology.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
19.12%
Tags
none
-
News
908 Devices Reports Third Quarter 2023 Financial Results and Narrows 2023 Revenue Outlook
Rhea-AI Summary
908 Devices Inc. (Nasdaq: MASS) reported $35.9 million in revenue for the first nine months of 2023, a 2% increase compared to 2022. The third quarter revenue was $14.3 million, a 9% decrease from the same period last year. The company expects full year 2023 revenue to be in the range of $49 million to $51 million, representing 4% to 9% growth over full year 2022.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
4.15%
Tags
earnings
-
News
908 Devices and Terumo Blood and Cell Technologies Collaborate to Add On-line Analytics to Quantum Flex Cell Expansion System
Rhea-AI Summary
908 Devices and Terumo Blood and Cell Technologies announce a collaboration to enable on-line monitoring of critical process parameters in Terumo BCT’s Quantum Flex Cell Expansion System. The collaboration aims to improve manufacturing efficiency and reduce costs in cell and gene therapy development. 908 Devices' MAVEN analyzer will be integrated into the Quantum Flex system to provide real-time monitoring and control of key process parameters.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
4.15%
Tags
none
News
908 Devices to Participate in Upcoming Investor Conferences
Rhea-AI Summary
908 Devices Inc. (Nasdaq: MASS) will participate in investor conferences including the 53rd Annual Baird Industrial Conference, Stifel Healthcare Conference 2023, and 25th Annual Stephens Investment Conference. The conferences will feature in-person presentations and fireside chats. Interested parties can access live and archived webcasts on the company website.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
12.95%
Tags
conferences
Stock MASS logo
908 Devices Inc

Nasdaq:MASS

MASS Rankings

#3830 Ranked by Market Cap
#5090 Ranked by Stock Gains
N/A Ranked by Dividends

MASS Stock Data

199.76M
24.68M
7.52%
86.42%
3.5%
Other Measuring and Controlling Device Manufacturing
Manufacturing
Link
United States
Boston

About MASS

908 devices, is democratizing chemical analysis by way of mass spectrometry, offering point-of-need chemical analysis devices ranging from rugged, handheld chemical detection tools to compact, tiny footprint analyzers and fast separation devices. these purpose-built and user-centric devices serve a range of industries including safety and security, oil & gas, life sciences and other applied markets. 908 devices is headquartered in the heart of boston where they research, design and manufacture innovative products based on high pressure mass spectrometry (hpms).